| Name | Title | Contact Details |
|---|
MedMen Enterprises is a leading cannabis company in the U.S. with assets and operations nationwide. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is the most recognized cannabis brand in the world today. MedMen brings class leading operational expertise and unprecedented investment to the fast changing and fast-growing cannabis industry as it moves from its gray market legacy to a fully regulated, legitimate and commercially viable market. Based in Los Angeles, MedMen employs over 1,100 team members across the U.S. It was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to redefine our society`s relationship with cannabis. The federal prohibition has had a disastrous impact, overpopulating our prisons and enriching violent drug cartels while keeping a relatively benign substance with proven benefits out of the reach of law abiding citizens. MedMen supports sensible, clear and just drug laws that strengthen communities and create economic opportunities. The company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates.
Together, making health care better for our communities.Setting a new standard in patient care excellence. Hospitals in the Capella Healthcare family will be the center point for transforming the quality of life in their communities, focusing first on improving the health and well-being of every individual.
HCI Hospital TV is a Loveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trimedyne is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.